Nuevocor

Nuevocor is a biotechnology company based in Singapore, focused on developing innovative gene therapies for genetic cardiomyopathies. The company aims to transform treatments for these heart muscle diseases, which can lead to heart failure, by using a mechanobiology-centered approach. Their proprietary PrOSIA platform identifies shared biomechanical pathways, allowing for therapies that address the root causes of these conditions.

Nuevocor's lead candidate, NVC-001, is a gene therapy designed to target LMNA-related dilated cardiomyopathy, a rare and aggressive disease. The therapy utilizes an AAV vector to disrupt the LINC complex, showing promising preclinical results in restoring cardiac function. The company's pipeline includes therapies for various genetic cardiomyopathies that are not treatable by traditional gene replacement methods. Founded by a team of experienced leaders, Nuevocor has raised significant funding to support its mission and has established operations in multiple regions, including the United States and Europe.